CERo Therapeutics Holdings, Inc.(CERO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CERO CERo Therapeutics Holdings, Inc.

Pre-Mkt 05-12 16:00:00 EDT Delay

{"stockData":{"symbol":"CERO","market":"US","secType":"STK","nameCN":"CERo Therapeutics Holdings, Inc.","latestPrice":0.027,"timestamp":1778616000000,"preClose":0.03055,"halted":0,"volume":397870,"delay":15,"changeRate":-0.11620294599018006,"floatShares":1762500,"shares":41876300,"eps":-22.583932,"marketStatus":"Pre-Mkt","change":-0.00355,"latestTime":"05-12 16:00:00 EDT Delay","open":0.0261,"high":0.032,"low":0.0261,"amount":10933.631675000004,"amplitude":0.193126,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-22.583932,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1778679000000},"marketStatusCode":1,"adr":0,"exchange":"OTCQB","adjPreClose":0.027,"volumeRatio":1.2477498661298885},"requestUrl":"/m/hq/s/CERO/wiki","defaultTab":"wiki","newsList":[{"id":"2634895892","title":"CERo Therapeutics escalates CER-1236 Phase 1 trial to 10 million cells/kg cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2634895892","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634895892?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:15","pubTimestamp":1778501747,"startTime":"0","endTime":"0","summary":"Cero Therapeutics completed dosing and 28-day safety follow-up for second ascending-dose cohort in Phase 1 CERTAIN-T trial of CER-1236 in blood cancers.Safety profile remained supportive of continued escalation, with no dose-limiting toxicities reported in this cohort.Prior interim safety observations were presented at Tandem Meetings in February, showing no severe treatment-related safety signals during dose-limiting toxicity monitoring.Enrollment has started for next higher-dose cohort, expected to expand patient mix to include myelodysplastic syndrome and myelofibrosis, broadening commercial and clinical positioning beyond initial acute myeloid leukemia focus.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL7bD92n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2095319765.USD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4139","SG9999014039.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","NDAQ","SG9999014013.SGD","BK4112","SG9999014021.USD","CERO","LU2210150020.SGD","BK4585","LU0314104364.USD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634878289","title":"Cero Therapeutics Completes Second Ascending Dose Cohort of Phase 1 Cer-1236 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2634878289","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634878289?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:15","pubTimestamp":1778501700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nTUACFDDRM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CERO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634128930","title":"Cero Therapeutics Holdings Inc - No Dose-Limiting Toxicities Observed at 4 × 10⁶ Cells/Kg Dose in Second Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2634128930","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634128930?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:15","pubTimestamp":1778501700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nTUACFDDRM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632647841","title":"Cero Therapeutics enters USD 1 million convertible note facility with Keystone Capital Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2632647841","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632647841?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:11","pubTimestamp":1777666295,"startTime":"0","endTime":"0","summary":"Cero Therapeutics entered convertible promissory note financing with Keystone Capital Partners on April 27, 2026.Keystone paid USD 400,000 for note with USD 500,000 principal face value.Facility allows additional borrowings up to USD 1 million in aggregate.Note carries 10% annual interest rate with maturity on April 27, 2027.Conversion price set at lesser of USD 0.05 or 80% of average of five lowest intraday prices over prior 20 trading days, subject to 4.99% beneficial ownership cap.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDLc2BPZh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CERO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629061523","title":"Cero Therapeutics director Francois Eric files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2629061523","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629061523?lang=en_us&edition=fundamental","pubTime":"2026-04-22 07:46","pubTimestamp":1776815207,"startTime":"0","endTime":"0","summary":"Cero Therapeutics filed an initial Form 3 for director Francois Eric dated Feb. 13, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 21, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL2p3z0D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CERO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627372002","title":"Cero Therapeutics FY25 net loss climbs 139.9% to $19.9 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2627372002","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627372002?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:10","pubTimestamp":1776283840,"startTime":"0","endTime":"0","summary":"Cero Therapeutics posted a net loss of $19.9 million for fiscal 2025, more than doubled from the prior year.R&D spending climbed 46.6% to $10.4 million as it prepared and filed the IND for CER-1236, then ran additional experiments in response to FDA questions.Cero ended 2025 with $1.7 million in cash and cash equivalents, warning available cash will not fund operations for 12 months after the filing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 15, 2026, and is solely responsible for the information co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL7sgH8Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CERO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627213634","title":"Cero Therapeutics sells $350,000 convertible note in private placement to Keystone Capital Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2627213634","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627213634?lang=en_us&edition=fundamental","pubTime":"2026-04-15 04:02","pubTimestamp":1776196955,"startTime":"0","endTime":"0","summary":"Cero Therapeutics sold an unregistered convertible promissory note to Keystone Capital Partners for USD 350,000, with USD 437,500 principal face value.Facility allows additional borrowings up to USD 1 million.Note carries 10% annual interest, with maturity set for April 9, 2027.Keystone can convert principal plus accrued interest into common stock at lower of USD 0.05 or 80% of average of five lowest intraday prices over prior 20 trading days.Conversion is subject to a 4.99% beneficial ownership cap.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Se","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL3XPZ6k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CERO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627445051","title":"Cero Therapeutics doses third patient in cohort 2 of Phase 1 CER-1236 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627445051","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627445051?lang=en_us&edition=fundamental","pubTime":"2026-04-14 20:15","pubTimestamp":1776168923,"startTime":"0","endTime":"0","summary":"CERo Therapeutics dosed third patient in Cohort 2 of Phase 1 CER-1236 trial, bringing total enrollment to six patients.Safety and early activity findings were already presented in February at Tandem Meetings, supporting continued dose escalation.Earlier readouts showed a favorable safety profile with no serious immune-related safety events reported.Data also indicated the therapy expanded in patients, with signs of potential clinical benefit in at least one heavily pretreated AML case.Protocol amendment expanded enrollment beyond AML into earlier-stage myelodysplastic syndrome and post-JAK inhibitor myelofibrosis, widening addressable patient populations for CER-1236.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDLjRRlR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210149790.SGD","LU0314104364.USD","SG9999014021.USD","IE00BN0W2V16.EUR","LU2210150020.SGD","IE00BN0W2W23.USD","BK4585","BK4139","IE00B64PRP62.GBP","SG9999014039.USD","BK4588","IE00BN0W2T93.GBP","SG9999014005.SGD","IE00B3QW5Z07.USD","BK4112","LU2095319765.USD","IE00BGHQF748.EUR","CERO","SG9999014013.SGD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627752445","title":"Cero Therapeutics Doses Third Patient in Cohort 2 of Phase 1 Cer-1236 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627752445","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627752445?lang=en_us&edition=fundamental","pubTime":"2026-04-14 20:15","pubTimestamp":1776168900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nTUACGHV11:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CERO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624494565","title":"Cero Therapeutics delays annual report filing after auditor change","url":"https://stock-news.laohu8.com/highlight/detail?id=2624494565","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624494565?lang=en_us&edition=fundamental","pubTime":"2026-04-02 04:11","pubTimestamp":1775074263,"startTime":"0","endTime":"0","summary":"CERo Therapeutics filed notice it will miss deadline for its fiscal year ended Dec. 31, 2025 annual report on Form 10-K.Delay follows engagement of a new independent auditor in February 2026, which needs more time to complete review of 2025 financial statements.Company expects to file Form 10-K within 15 calendar days of prescribed due date.Preliminary results point to net loss of $19.9 million, versus $8.3 million a year earlier.Cash used in operating activities is estimated at $16.2 million, versus $12.9 million in prior year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDLbbpZC8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CERO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623113317","title":"CERo Therapeutics doses second patient in Cohort 2 of Phase 1 CER-1236 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2623113317","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623113317?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:15","pubTimestamp":1774872929,"startTime":"0","endTime":"0","summary":"CERo Therapeutics dosed second patient in Cohort 2 of Phase 1 CER-1236 trial in hematologic malignancies, bringing total treated to five.Safety, pharmacokinetic, pharmacodynamic, and clinical activity monitoring continues, with more than seven days of follow-up completed for Cohort 2 second patient.Prior interim results were presented at February Tandem Meetings, showing no cytokine release syndrome or neurotoxicity of any grade, no dose-limiting toxicities in 28-day window, and in vivo expansion peaking on days 10-14.Clinical observation from one inv AML patient presented in February showed 72 consecutive days of platelet transfusion independence following four infusions over five months at lowest dose.Protocol amendment expands enrollment beyond AML into transfusion-dependent or high-risk MDS, plus post-JAK-inhibitor myelofibrosis, supporting continued dose escalation and planned expansion phase.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL6kwMTx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","NDAQ","BK4585","SG9999014005.SGD","IE00BGHQF748.EUR","CERO","LU2095319765.USD","BK4139","IE00B3QW5Z07.USD","SG9999014021.USD","LU0314104364.USD","BK4588","LU2210150020.SGD","BK4112","SG9999014013.SGD","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623317129","title":"Cero Therapeutics Doses Second Patient in Cohort 2 of Phase 1 Cer-1236 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2623317129","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623317129?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:15","pubTimestamp":1774872900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA7FNPCS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618942547","title":"Cero Therapeutics Holdings Inc: Considering Other Potential Paths for Relisting on a National Securities Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=2618942547","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618942547?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:16","pubTimestamp":1773231365,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nFWN3ZZ0AL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CERO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618544942","title":"Cero Therapeutics: Engaged With Investment Bank to Raise Capital & Pursue a Strategy to Support Potential Relisting on Nasdaq Capital Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2618544942","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618544942?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:16","pubTimestamp":1773231365,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nFWN3ZZ0AL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618942516","title":"Cero Therapeutics appoints Eric Francois to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2618942516","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618942516?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:15","pubTimestamp":1773231315,"startTime":"0","endTime":"0","summary":"Cero Therapeutics said it appointed Eric Francois to its board of directors. Francois has experience in life sciences finance, capital markets, and corporate development, including capital raising, M&A, and strategic partnerships. The company said Francois was involved in discussions with its new investment bank and is assisting with funding opportunities and operational improvements.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDLj0BDr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4112","LU2210149790.SGD","LU2095319765.USD","LU0314104364.USD","NDAQ","BK4588","SG9999014013.SGD","SG9999014039.USD","LU2210150020.SGD","SG9999014021.USD","IE00BGHQF748.EUR","CERO","SG9999014005.SGD","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618425499","title":"Cero Therapeutics Provides Shareholder Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2618425499","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618425499?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:15","pubTimestamp":1773231300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nTUA6LSVZY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CERO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618943494","title":"Cero Therapeutics issues USD 0.75 million convertible note to Keystone Capital Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2618943494","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618943494?lang=en_us&edition=fundamental","pubTime":"2026-03-11 18:02","pubTimestamp":1773223372,"startTime":"0","endTime":"0","summary":"Cero Therapeutics entered a convertible promissory note financing with Keystone Capital Partners on March 6, 2026. The note was issued for a purchase price of USD 0.75 million and has a principal face value of USD 0.94 million. Under the note, Cero Therapeutics may borrow up to an aggregate maximum of USD 1 million and the note bears interest at 10%. The note matures on August 6, 2027 and is convertible into common stock at the lesser of USD 0.05 and 80% of a specified trading-price formula.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL4wbvqz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CERO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612525884","title":"Cero Therapeutics Announces Biotech Industry Veteran Eric Francois to   Join Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2612525884","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612525884?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:00","pubTimestamp":1771333206,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA54NCQZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608607853","title":"Cero Therapeutics to present data from Phase 2 trial of CER-1236","url":"https://stock-news.laohu8.com/highlight/detail?id=2608607853","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608607853?lang=en_us&edition=fundamental","pubTime":"2026-02-04 22:16","pubTimestamp":1770214617,"startTime":"0","endTime":"0","summary":"CERo Therapeutics (CERO) announces a presentation highlighting data to date from the Company’s Phase 1 clinical trial, called CERTAIN-T, of its lea...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cero-therapeutics-to-present-data-from-phase-2-trial-of-cer-1236-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cero-therapeutics-to-present-data-from-phase-2-trial-of-cer-1236-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CERO","LENZ","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608788389","title":"BRIEF-Cero Therapeutics Hearing Review Council Issued Decision","url":"https://stock-news.laohu8.com/highlight/detail?id=2608788389","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608788389?lang=en_us&edition=fundamental","pubTime":"2026-02-04 07:23","pubTimestamp":1770161009,"startTime":"0","endTime":"0","summary":"BRIEF-Cero Therapeutics Hearing Review Council Issued Decision Feb 3  - CERo Therapeutics Holdings Inc CERO.PK:CERO THERAPEUTICS: HEARING REVIEW COUNCIL ISSUED DECISION AFFIRMING NASDAQ HEARING PANEL'S DECISION TO DELIST COMPANY’S SECURITIES FROM NASDAQSource text: [ID:n0001213900-26-011587]Further company coverage: CERO.PK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nFWN3YZ17Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CERO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cero.bio","description":"CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.","exchange":"OTCQB","name":"CERo Therapeutics Holdings, Inc.","nameEN":"CERo Therapeutics Holdings, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CERo Therapeutics Holdings, Inc.(CERO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CERo Therapeutics Holdings, Inc.(CERO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CERo Therapeutics Holdings, Inc.,CERO,CERo Therapeutics Holdings, Inc.股票,CERo Therapeutics Holdings, Inc.股票老虎,CERo Therapeutics Holdings, Inc.股票老虎国际,CERo Therapeutics Holdings, Inc.行情,CERo Therapeutics Holdings, Inc.股票行情,CERo Therapeutics Holdings, Inc.股价,CERo Therapeutics Holdings, Inc.股市,CERo Therapeutics Holdings, Inc.股票价格,CERo Therapeutics Holdings, Inc.股票交易,CERo Therapeutics Holdings, Inc.股票购买,CERo Therapeutics Holdings, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CERo Therapeutics Holdings, Inc.(CERO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CERo Therapeutics Holdings, Inc.(CERO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction